Clinical Trial Update: A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Autism-Related Irritability in Adolescents, Respectively [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update describing long-term safety and tolerability assessments of KarXT and KarX-EC for schizophrenia and autism-related irritability …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autism Spectrum Disorder
• Schizophrenia

Drugs mentioned

• KarX-EC
• KarXT (xanomeline-trospium)

Snippet

Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company | Conditions: Schizophrenia, Autism-Related Irritability | Phase 3 | Status: RECRUITING